nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—Cytarabine—lymphatic system cancer	0.05	0.318	CbGbCtD
Alfuzosin—CYP3A4—Teniposide—lymphatic system cancer	0.0493	0.313	CbGbCtD
Alfuzosin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0345	0.219	CbGbCtD
Alfuzosin—CYP3A4—Vincristine—lymphatic system cancer	0.0237	0.151	CbGbCtD
Alfuzosin—Coronary artery disease—Vincristine—lymphatic system cancer	0.0203	0.0241	CcSEcCtD
Alfuzosin—Stomach ache—Mitoxantrone—lymphatic system cancer	0.0184	0.0218	CcSEcCtD
Alfuzosin—Neuropathy—Teniposide—lymphatic system cancer	0.014	0.0166	CcSEcCtD
Alfuzosin—Jaundice—Mechlorethamine—lymphatic system cancer	0.011	0.0131	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00858	0.0102	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00819	0.00972	CcSEcCtD
Alfuzosin—Angina pectoris—Fludarabine—lymphatic system cancer	0.00802	0.00952	CcSEcCtD
Alfuzosin—Sweating—Teniposide—lymphatic system cancer	0.00801	0.00951	CcSEcCtD
Alfuzosin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00796	0.00944	CcSEcCtD
Alfuzosin—Bronchitis—Fludarabine—lymphatic system cancer	0.00792	0.0094	CcSEcCtD
Alfuzosin—Neuropathy—Carmustine—lymphatic system cancer	0.00789	0.00936	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00765	0.00909	CcSEcCtD
Alfuzosin—Injury—Bleomycin—lymphatic system cancer	0.0076	0.00902	CcSEcCtD
Alfuzosin—Neuropathy—Vincristine—lymphatic system cancer	0.00753	0.00894	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00749	0.00889	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.0072	0.00854	CcSEcCtD
Alfuzosin—Arthritis—Bleomycin—lymphatic system cancer	0.00719	0.00853	CcSEcCtD
Alfuzosin—Infection—Mechlorethamine—lymphatic system cancer	0.00718	0.00852	CcSEcCtD
Alfuzosin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00708	0.0084	CcSEcCtD
Alfuzosin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00702	0.00833	CcSEcCtD
Alfuzosin—Flushing—Teniposide—lymphatic system cancer	0.00696	0.00826	CcSEcCtD
Alfuzosin—Sinusitis—Fludarabine—lymphatic system cancer	0.00689	0.00818	CcSEcCtD
Alfuzosin—Injury—Carmustine—lymphatic system cancer	0.00663	0.00788	CcSEcCtD
Alfuzosin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00654	0.00777	CcSEcCtD
Alfuzosin—Chest pain—Teniposide—lymphatic system cancer	0.00556	0.0066	CcSEcCtD
Alfuzosin—Oedema—Teniposide—lymphatic system cancer	0.00533	0.00633	CcSEcCtD
Alfuzosin—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00532	0.00632	CcSEcCtD
Alfuzosin—Infection—Teniposide—lymphatic system cancer	0.00529	0.00628	CcSEcCtD
Alfuzosin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00522	0.00619	CcSEcCtD
Alfuzosin—Tachycardia—Teniposide—lymphatic system cancer	0.0052	0.00617	CcSEcCtD
Alfuzosin—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00518	0.00615	CcSEcCtD
Alfuzosin—Malaise—Fludarabine—lymphatic system cancer	0.00517	0.00614	CcSEcCtD
Alfuzosin—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00515	0.00611	CcSEcCtD
Alfuzosin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00511	0.00607	CcSEcCtD
Alfuzosin—Hypotension—Teniposide—lymphatic system cancer	0.00498	0.00591	CcSEcCtD
Alfuzosin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00495	0.00587	CcSEcCtD
Alfuzosin—Arthralgia—Fludarabine—lymphatic system cancer	0.00489	0.0058	CcSEcCtD
Alfuzosin—Discomfort—Fludarabine—lymphatic system cancer	0.00483	0.00573	CcSEcCtD
Alfuzosin—Oedema—Fludarabine—lymphatic system cancer	0.00468	0.00556	CcSEcCtD
Alfuzosin—Infection—Fludarabine—lymphatic system cancer	0.00465	0.00552	CcSEcCtD
Alfuzosin—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00463	0.0055	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00461	0.00547	CcSEcCtD
Alfuzosin—Vomiting—Mechlorethamine—lymphatic system cancer	0.0046	0.00545	CcSEcCtD
Alfuzosin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00459	0.00545	CcSEcCtD
Alfuzosin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00459	0.00544	CcSEcCtD
Alfuzosin—Rash—Mechlorethamine—lymphatic system cancer	0.00456	0.00541	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00455	0.00541	CcSEcCtD
Alfuzosin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00455	0.0054	CcSEcCtD
Alfuzosin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00453	0.00537	CcSEcCtD
Alfuzosin—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00451	0.00536	CcSEcCtD
Alfuzosin—Flushing—Bleomycin—lymphatic system cancer	0.00449	0.00532	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.0044	0.00522	CcSEcCtD
Alfuzosin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00439	0.00521	CcSEcCtD
Alfuzosin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00437	0.00519	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00436	0.00517	CcSEcCtD
Alfuzosin—Sweating—Vincristine—lymphatic system cancer	0.0043	0.00511	CcSEcCtD
Alfuzosin—Nausea—Mechlorethamine—lymphatic system cancer	0.00429	0.0051	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00427	0.00506	CcSEcCtD
Alfuzosin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00426	0.00505	CcSEcCtD
Alfuzosin—Urticaria—Teniposide—lymphatic system cancer	0.00423	0.00502	CcSEcCtD
Alfuzosin—Abdominal pain—Teniposide—lymphatic system cancer	0.00421	0.005	CcSEcCtD
Alfuzosin—Sweating—Mitoxantrone—lymphatic system cancer	0.00419	0.00497	CcSEcCtD
Alfuzosin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00415	0.00492	CcSEcCtD
Alfuzosin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00412	0.00489	CcSEcCtD
Alfuzosin—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0041	0.00487	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00404	0.0048	CcSEcCtD
Alfuzosin—Fatigue—Fludarabine—lymphatic system cancer	0.00404	0.00479	CcSEcCtD
Alfuzosin—Pain—Fludarabine—lymphatic system cancer	0.004	0.00475	CcSEcCtD
Alfuzosin—Constipation—Fludarabine—lymphatic system cancer	0.004	0.00475	CcSEcCtD
Alfuzosin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00398	0.00472	CcSEcCtD
Alfuzosin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00396	0.0047	CcSEcCtD
Alfuzosin—Urethral disorder—Vincristine—lymphatic system cancer	0.00395	0.00469	CcSEcCtD
Alfuzosin—Eye disorder—Carmustine—lymphatic system cancer	0.00394	0.00468	CcSEcCtD
Alfuzosin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00393	0.00467	CcSEcCtD
Alfuzosin—Flushing—Carmustine—lymphatic system cancer	0.00392	0.00465	CcSEcCtD
Alfuzosin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0039	0.00463	CcSEcCtD
Alfuzosin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00389	0.00462	CcSEcCtD
Alfuzosin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00386	0.00458	CcSEcCtD
Alfuzosin—Asthenia—Teniposide—lymphatic system cancer	0.00382	0.00454	CcSEcCtD
Alfuzosin—Malaise—Bleomycin—lymphatic system cancer	0.00379	0.0045	CcSEcCtD
Alfuzosin—Pruritus—Teniposide—lymphatic system cancer	0.00377	0.00447	CcSEcCtD
Alfuzosin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00374	0.00444	CcSEcCtD
Alfuzosin—Mental disorder—Carmustine—lymphatic system cancer	0.0037	0.00439	CcSEcCtD
Alfuzosin—Angiopathy—Vincristine—lymphatic system cancer	0.00365	0.00434	CcSEcCtD
Alfuzosin—Diarrhoea—Teniposide—lymphatic system cancer	0.00365	0.00433	CcSEcCtD
Alfuzosin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00363	0.00431	CcSEcCtD
Alfuzosin—Chest pain—Bleomycin—lymphatic system cancer	0.00358	0.00425	CcSEcCtD
Alfuzosin—Back pain—Carmustine—lymphatic system cancer	0.00355	0.00422	CcSEcCtD
Alfuzosin—Discomfort—Bleomycin—lymphatic system cancer	0.00354	0.0042	CcSEcCtD
Alfuzosin—Mental disorder—Vincristine—lymphatic system cancer	0.00353	0.00419	CcSEcCtD
Alfuzosin—Oedema—Bleomycin—lymphatic system cancer	0.00343	0.00408	CcSEcCtD
Alfuzosin—Infection—Bleomycin—lymphatic system cancer	0.00341	0.00405	CcSEcCtD
Alfuzosin—Back pain—Vincristine—lymphatic system cancer	0.00339	0.00403	CcSEcCtD
Alfuzosin—Vomiting—Teniposide—lymphatic system cancer	0.00339	0.00402	CcSEcCtD
Alfuzosin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00336	0.00399	CcSEcCtD
Alfuzosin—Asthenia—Fludarabine—lymphatic system cancer	0.00336	0.00399	CcSEcCtD
Alfuzosin—Rash—Teniposide—lymphatic system cancer	0.00336	0.00399	CcSEcCtD
Alfuzosin—Dermatitis—Teniposide—lymphatic system cancer	0.00336	0.00398	CcSEcCtD
Alfuzosin—Headache—Teniposide—lymphatic system cancer	0.00334	0.00396	CcSEcCtD
Alfuzosin—Pruritus—Fludarabine—lymphatic system cancer	0.00331	0.00393	CcSEcCtD
Alfuzosin—Back pain—Mitoxantrone—lymphatic system cancer	0.0033	0.00392	CcSEcCtD
Alfuzosin—Hypotension—Bleomycin—lymphatic system cancer	0.00321	0.00381	CcSEcCtD
Alfuzosin—Diarrhoea—Fludarabine—lymphatic system cancer	0.0032	0.0038	CcSEcCtD
Alfuzosin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00317	0.00376	CcSEcCtD
Alfuzosin—Nausea—Teniposide—lymphatic system cancer	0.00317	0.00376	CcSEcCtD
Alfuzosin—Vertigo—Vincristine—lymphatic system cancer	0.00315	0.00374	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00313	0.00371	CcSEcCtD
Alfuzosin—Chest pain—Carmustine—lymphatic system cancer	0.00313	0.00371	CcSEcCtD
Alfuzosin—Malaise—Mitoxantrone—lymphatic system cancer	0.00308	0.00365	CcSEcCtD
Alfuzosin—Oedema—Carmustine—lymphatic system cancer	0.003	0.00356	CcSEcCtD
Alfuzosin—Infection—Carmustine—lymphatic system cancer	0.00298	0.00353	CcSEcCtD
Alfuzosin—Vomiting—Fludarabine—lymphatic system cancer	0.00298	0.00353	CcSEcCtD
Alfuzosin—Rash—Fludarabine—lymphatic system cancer	0.00295	0.0035	CcSEcCtD
Alfuzosin—Dermatitis—Fludarabine—lymphatic system cancer	0.00295	0.0035	CcSEcCtD
Alfuzosin—Pain—Bleomycin—lymphatic system cancer	0.00294	0.00349	CcSEcCtD
Alfuzosin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00293	0.00348	CcSEcCtD
Alfuzosin—Headache—Fludarabine—lymphatic system cancer	0.00293	0.00348	CcSEcCtD
Alfuzosin—Tachycardia—Carmustine—lymphatic system cancer	0.00293	0.00347	CcSEcCtD
Alfuzosin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00291	0.00345	CcSEcCtD
Alfuzosin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00291	0.00345	CcSEcCtD
Alfuzosin—Discomfort—Mitoxantrone—lymphatic system cancer	0.00287	0.00341	CcSEcCtD
Alfuzosin—Oedema—Vincristine—lymphatic system cancer	0.00286	0.0034	CcSEcCtD
Alfuzosin—Infection—Vincristine—lymphatic system cancer	0.00284	0.00337	CcSEcCtD
Alfuzosin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00283	0.00336	CcSEcCtD
Alfuzosin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00282	0.00335	CcSEcCtD
Alfuzosin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00281	0.00333	CcSEcCtD
Alfuzosin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0028	0.00333	CcSEcCtD
Alfuzosin—Hypotension—Carmustine—lymphatic system cancer	0.0028	0.00332	CcSEcCtD
Alfuzosin—Oedema—Mitoxantrone—lymphatic system cancer	0.00279	0.00331	CcSEcCtD
Alfuzosin—Nausea—Fludarabine—lymphatic system cancer	0.00278	0.0033	CcSEcCtD
Alfuzosin—Infection—Mitoxantrone—lymphatic system cancer	0.00277	0.00329	CcSEcCtD
Alfuzosin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00277	0.00328	CcSEcCtD
Alfuzosin—Shock—Mitoxantrone—lymphatic system cancer	0.00274	0.00325	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00273	0.00324	CcSEcCtD
Alfuzosin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00273	0.00324	CcSEcCtD
Alfuzosin—Urticaria—Bleomycin—lymphatic system cancer	0.00273	0.00324	CcSEcCtD
Alfuzosin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00272	0.00323	CcSEcCtD
Alfuzosin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00271	0.00321	CcSEcCtD
Alfuzosin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00269	0.0032	CcSEcCtD
Alfuzosin—Hypotension—Vincristine—lymphatic system cancer	0.00267	0.00317	CcSEcCtD
Alfuzosin—Somnolence—Carmustine—lymphatic system cancer	0.00266	0.00316	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00261	0.00309	CcSEcCtD
Alfuzosin—Hypotension—Mitoxantrone—lymphatic system cancer	0.0026	0.00309	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00259	0.00307	CcSEcCtD
Alfuzosin—Pain—Carmustine—lymphatic system cancer	0.00256	0.00304	CcSEcCtD
Alfuzosin—Constipation—Carmustine—lymphatic system cancer	0.00256	0.00304	CcSEcCtD
Alfuzosin—Breast disorder—Methotrexate—lymphatic system cancer	0.00255	0.00303	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00254	0.00302	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00254	0.00301	CcSEcCtD
Alfuzosin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00248	0.00294	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00247	0.00293	CcSEcCtD
Alfuzosin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00247	0.00293	CcSEcCtD
Alfuzosin—Fatigue—Vincristine—lymphatic system cancer	0.00247	0.00293	CcSEcCtD
Alfuzosin—Asthenia—Bleomycin—lymphatic system cancer	0.00246	0.00292	CcSEcCtD
Alfuzosin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00245	0.00291	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00245	0.00291	CcSEcCtD
Alfuzosin—Pain—Vincristine—lymphatic system cancer	0.00245	0.0029	CcSEcCtD
Alfuzosin—Constipation—Vincristine—lymphatic system cancer	0.00245	0.0029	CcSEcCtD
Alfuzosin—Pruritus—Bleomycin—lymphatic system cancer	0.00243	0.00288	CcSEcCtD
Alfuzosin—Fatigue—Mitoxantrone—lymphatic system cancer	0.0024	0.00285	CcSEcCtD
Alfuzosin—Pain—Mitoxantrone—lymphatic system cancer	0.00238	0.00283	CcSEcCtD
Alfuzosin—Constipation—Mitoxantrone—lymphatic system cancer	0.00238	0.00283	CcSEcCtD
Alfuzosin—Abdominal pain—Carmustine—lymphatic system cancer	0.00237	0.00281	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00234	0.00278	CcSEcCtD
Alfuzosin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0023	0.00273	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00228	0.0027	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00227	0.00269	CcSEcCtD
Alfuzosin—Abdominal pain—Vincristine—lymphatic system cancer	0.00226	0.00268	CcSEcCtD
Alfuzosin—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00225	0.00267	CcSEcCtD
Alfuzosin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00221	0.00263	CcSEcCtD
Alfuzosin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0022	0.00261	CcSEcCtD
Alfuzosin—Vomiting—Bleomycin—lymphatic system cancer	0.00218	0.00259	CcSEcCtD
Alfuzosin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00218	0.00258	CcSEcCtD
Alfuzosin—Infestation—Methotrexate—lymphatic system cancer	0.00218	0.00258	CcSEcCtD
Alfuzosin—Drowsiness—Methotrexate—lymphatic system cancer	0.00218	0.00258	CcSEcCtD
Alfuzosin—Rash—Bleomycin—lymphatic system cancer	0.00216	0.00257	CcSEcCtD
Alfuzosin—Dermatitis—Bleomycin—lymphatic system cancer	0.00216	0.00257	CcSEcCtD
Alfuzosin—Asthenia—Carmustine—lymphatic system cancer	0.00215	0.00255	CcSEcCtD
Alfuzosin—Sweating—Methotrexate—lymphatic system cancer	0.00209	0.00248	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00206	0.00244	CcSEcCtD
Alfuzosin—Asthenia—Vincristine—lymphatic system cancer	0.00205	0.00244	CcSEcCtD
Alfuzosin—Diarrhoea—Carmustine—lymphatic system cancer	0.00205	0.00243	CcSEcCtD
Alfuzosin—Nausea—Bleomycin—lymphatic system cancer	0.00204	0.00242	CcSEcCtD
Alfuzosin—Asthenia—Mitoxantrone—lymphatic system cancer	0.002	0.00237	CcSEcCtD
Alfuzosin—Dizziness—Carmustine—lymphatic system cancer	0.00198	0.00235	CcSEcCtD
Alfuzosin—Diarrhoea—Vincristine—lymphatic system cancer	0.00196	0.00232	CcSEcCtD
Alfuzosin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00194	0.0023	CcSEcCtD
Alfuzosin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00193	0.00229	CcSEcCtD
Alfuzosin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00192	0.00227	CcSEcCtD
Alfuzosin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00191	0.00226	CcSEcCtD
Alfuzosin—Vomiting—Carmustine—lymphatic system cancer	0.00191	0.00226	CcSEcCtD
Alfuzosin—Dizziness—Vincristine—lymphatic system cancer	0.00189	0.00225	CcSEcCtD
Alfuzosin—Rash—Carmustine—lymphatic system cancer	0.00189	0.00224	CcSEcCtD
Alfuzosin—Dermatitis—Carmustine—lymphatic system cancer	0.00189	0.00224	CcSEcCtD
Alfuzosin—Headache—Carmustine—lymphatic system cancer	0.00188	0.00223	CcSEcCtD
Alfuzosin—Eye disorder—Methotrexate—lymphatic system cancer	0.00183	0.00217	CcSEcCtD
Alfuzosin—Vomiting—Vincristine—lymphatic system cancer	0.00182	0.00216	CcSEcCtD
Alfuzosin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00181	0.00215	CcSEcCtD
Alfuzosin—Rash—Vincristine—lymphatic system cancer	0.0018	0.00214	CcSEcCtD
Alfuzosin—Dermatitis—Vincristine—lymphatic system cancer	0.0018	0.00214	CcSEcCtD
Alfuzosin—Headache—Vincristine—lymphatic system cancer	0.00179	0.00213	CcSEcCtD
Alfuzosin—Nausea—Carmustine—lymphatic system cancer	0.00178	0.00211	CcSEcCtD
Alfuzosin—Angiopathy—Methotrexate—lymphatic system cancer	0.00177	0.0021	CcSEcCtD
Alfuzosin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00177	0.0021	CcSEcCtD
Alfuzosin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00176	0.00209	CcSEcCtD
Alfuzosin—Rash—Mitoxantrone—lymphatic system cancer	0.00176	0.00209	CcSEcCtD
Alfuzosin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00176	0.00208	CcSEcCtD
Alfuzosin—Headache—Mitoxantrone—lymphatic system cancer	0.00175	0.00207	CcSEcCtD
Alfuzosin—Mental disorder—Methotrexate—lymphatic system cancer	0.00171	0.00203	CcSEcCtD
Alfuzosin—Nausea—Vincristine—lymphatic system cancer	0.0017	0.00202	CcSEcCtD
Alfuzosin—Nausea—Mitoxantrone—lymphatic system cancer	0.00166	0.00196	CcSEcCtD
Alfuzosin—Back pain—Methotrexate—lymphatic system cancer	0.00165	0.00195	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00158	0.00187	CcSEcCtD
Alfuzosin—Malaise—Methotrexate—lymphatic system cancer	0.00153	0.00182	CcSEcCtD
Alfuzosin—Vertigo—Methotrexate—lymphatic system cancer	0.00153	0.00181	CcSEcCtD
Alfuzosin—Arthralgia—Methotrexate—lymphatic system cancer	0.00145	0.00172	CcSEcCtD
Alfuzosin—Chest pain—Methotrexate—lymphatic system cancer	0.00145	0.00172	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00144	0.00171	CcSEcCtD
Alfuzosin—Discomfort—Methotrexate—lymphatic system cancer	0.00143	0.0017	CcSEcCtD
Alfuzosin—Infection—Methotrexate—lymphatic system cancer	0.00138	0.00164	CcSEcCtD
Alfuzosin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00136	0.00162	CcSEcCtD
Alfuzosin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00136	0.00161	CcSEcCtD
Alfuzosin—Skin disorder—Methotrexate—lymphatic system cancer	0.00135	0.0016	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00134	0.00159	CcSEcCtD
Alfuzosin—Hypotension—Methotrexate—lymphatic system cancer	0.0013	0.00154	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00126	0.0015	CcSEcCtD
Alfuzosin—Somnolence—Methotrexate—lymphatic system cancer	0.00123	0.00146	CcSEcCtD
Alfuzosin—Dyspepsia—Methotrexate—lymphatic system cancer	0.00122	0.00145	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.0012	0.00142	CcSEcCtD
Alfuzosin—Fatigue—Methotrexate—lymphatic system cancer	0.0012	0.00142	CcSEcCtD
Alfuzosin—Pain—Methotrexate—lymphatic system cancer	0.00119	0.00141	CcSEcCtD
Alfuzosin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00114	0.00136	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00114	0.00135	CcSEcCtD
Alfuzosin—Urticaria—Methotrexate—lymphatic system cancer	0.0011	0.00131	CcSEcCtD
Alfuzosin—Abdominal pain—Methotrexate—lymphatic system cancer	0.0011	0.0013	CcSEcCtD
Alfuzosin—Asthenia—Methotrexate—lymphatic system cancer	0.000996	0.00118	CcSEcCtD
Alfuzosin—Pruritus—Methotrexate—lymphatic system cancer	0.000982	0.00117	CcSEcCtD
Alfuzosin—Diarrhoea—Methotrexate—lymphatic system cancer	0.00095	0.00113	CcSEcCtD
Alfuzosin—Dizziness—Methotrexate—lymphatic system cancer	0.000918	0.00109	CcSEcCtD
Alfuzosin—Vomiting—Methotrexate—lymphatic system cancer	0.000883	0.00105	CcSEcCtD
Alfuzosin—Rash—Methotrexate—lymphatic system cancer	0.000875	0.00104	CcSEcCtD
Alfuzosin—Dermatitis—Methotrexate—lymphatic system cancer	0.000875	0.00104	CcSEcCtD
Alfuzosin—Headache—Methotrexate—lymphatic system cancer	0.00087	0.00103	CcSEcCtD
Alfuzosin—Nausea—Methotrexate—lymphatic system cancer	0.000825	0.000979	CcSEcCtD
